This report was first published by Endpoints News. To see the original version, click here
A US-China biotech has reeled in $130 million for three biologics in clinical testing for musculoskeletal diseases, including one in which Ultragenyx recently came up short.
Angitia Biopharmaceuticals disclosed its Series D on Thursday morning, about 14 months after a $120 million Series C. The nearly eight-year-old drug developer has now raised $454 million since its founding, the company told Endpoints News. It has nearly 100 employees across operations in Westlake Village, CA, and Guangzhou, China.
您已阅读19%（595字），剩余81%（2587字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。